An open-label study of patients with relapsing forms of MS designed to assess the biochemical, immunicological, and pharmacokinetic profiles of a large, actively infusing natalizumab patient cohort.
The objective of this study was to evaluate the efficacy of natilizumab on the quality of life, neurologic function, and neuroradiographic study in patients with relapsing MS in a clinic practice setting.
63rd American Academy of Neurology (AAN) Annual Meeting
Apr 9, 2011 - Apr 16, 2011, Honolulu, Hawaii
The objective of this study was to identify markers related to increased risk of progressive multifocal leukoencephalopathy (PML) associated with natalizumab therapy which may aid in PML risk stratification.